BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
By: Benzinga
February 04, 2013 at 13:17 PM EST
Jefferies Reiterates Buy Rating, $32 PT on ICON plc on Clinical Trial Staffing Acquisition
In a report published Monday, Jefferies reiterated its Buy rating and $32.00 price target on ICON plc (NASDAQ: ICLR ). Jefferies noted, “ICON has entered into an agreement to buy Cross Country Healthcare's (CCRN, $5.60, NC) clinical trial segment. For the nine-months ending September 30, 2012 the segment generated $51.2M
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here